Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IWWM-11 2022 | The importance of testing for cryoglobulinemia in Waldenström’s macroglobulinemia patients

Shirley D’Sa • 29 Oct 2022
IWWM-11 2022
Lymphoma Non-Hodgkin Lymphoma Rare Diseases Waldenström’s Macroglobulinemia

In this video, Shirley D’Sa, MD, FRCP, FRCPath, University College London Hospitals NHS Foundation Trust, London, UK, highlights the importance of testing for cryoglobulinemia in patients with Waldenström’s macroglobulinemia (WM), and challenges in this space. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Janssen- speaker fees, research grants, congress support, advisory boards
BeiGene- speaker fees, research grants, congress support, advisory boards
Sanofi- speaker fees, advisory boards

More from Shirley D’Sa

Should TP53 mutations be used to guide treatment decisions in Waldenström’s macroglobulinemia? 4:03
Should TP53 mutations be used to guide treatment decisions in Waldenström’s macroglobulinemia?
Shirley D’Sa • 1 Nov 2024
IgM de-myelinating neuropathy as a complication of MGUS and WM 5:22
IgM de-myelinating neuropathy as a complication of MGUS and WM
Shirley D’Sa • 1 Nov 2024
The ethnic diversity in the presentation and outcome of WM and MGUS in the United Kingdom 4:18
The ethnic diversity in the presentation and outcome of WM and MGUS in the United Kingdom
Shirley D’Sa • 1 Nov 2024
Clinical outcomes of patients with WM treated with bortezomib in the UK R2W study 1:03
Clinical outcomes of patients with WM treated with bortezomib in the UK R2W study
Shirley D’Sa • 29 Oct 2022

Related Videos

A Phase I/II study of acalabrutinib, venetoclax, & obinutuzumab in R/R and treatment-naive MCL 4:43
A Phase I/II study of acalabrutinib, venetoclax, & obinutuzumab in R/R and treatment-naive MCL
Austin Kim • 6 Dec 2025
Press briefing: primary results from the Phase III EPCORE FL-1 trial 8:41
Press briefing: primary results from the Phase III EPCORE FL-1 trial
Lorenzo Falchi • 6 Dec 2025
BGB-16673 in patients with R/R CLL/SLL: updated results from the ongoing Phase I CaDAnCe-101 study 1:41
BGB-16673 in patients with R/R CLL/SLL: updated results from the ongoing Phase I CaDAnCe-101 study
Inhye Ahn • 6 Dec 2025
Long-term follow-up results of Mosun-Pola versus R-Pola in patients with R/R LBCL 6:42
Long-term follow-up results of Mosun-Pola versus R-Pola in patients with R/R LBCL
Nilanjan Ghosh • 10 Dec 2025
The content of VJHemOnc is intended for healthcare professionals